Equities analysts expect Accuray Incorporated (NASDAQ:ARAY) to post sales of $91.29 million for the current quarter, according to Zacks. Two analysts have issued estimates for Accuray’s earnings, with the lowest sales estimate coming in at $90.58 million and the highest estimate coming in at $92.00 million. Accuray reported sales of $87.50 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.3%. The company is expected to issue its next quarterly earnings results on Tuesday, January 30th.

According to Zacks, analysts expect that Accuray will report full-year sales of $91.29 million for the current year, with estimates ranging from $397.70 million to $398.53 million. For the next fiscal year, analysts forecast that the firm will post sales of $415.27 million per share, with estimates ranging from $415.03 million to $415.50 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Accuray.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The business had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) EPS.

A number of research firms have commented on ARAY. Jefferies Group reaffirmed a “buy” rating and set a $7.00 price target on shares of Accuray in a research report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 price target on shares of Accuray in a research report on Thursday, August 24th. Lake Street Capital began coverage on Accuray in a research report on Thursday. They set a “buy” rating and a $10.00 price target for the company. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Thursday, August 24th. Finally, Zacks Investment Research raised Accuray from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $6.82.

In other news, CEO Joshua Levine sold 17,093 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.86, for a total value of $83,071.98. Following the completion of the transaction, the chief executive officer now owns 1,435,428 shares of the company’s stock, valued at approximately $6,976,180.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kelly Londy sold 99,136 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total value of $420,336.64. The disclosure for this sale can be found here. Insiders sold a total of 125,549 shares of company stock valued at $550,135 in the last three months. Corporate insiders own 3.90% of the company’s stock.

Several large investors have recently made changes to their positions in ARAY. Vident Investment Advisory LLC raised its position in shares of Accuray by 75.4% in the 3rd quarter. Vident Investment Advisory LLC now owns 4,899,643 shares of the medical equipment provider’s stock worth $19,599,000 after acquiring an additional 2,106,215 shares in the last quarter. Neuberger Berman Group LLC raised its position in shares of Accuray by 9.9% in the 3rd quarter. Neuberger Berman Group LLC now owns 5,272,695 shares of the medical equipment provider’s stock worth $21,091,000 after acquiring an additional 473,008 shares in the last quarter. Boston Partners raised its position in shares of Accuray by 22.2% in the 3rd quarter. Boston Partners now owns 2,276,184 shares of the medical equipment provider’s stock worth $9,105,000 after acquiring an additional 414,070 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Accuray by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 6,447,130 shares of the medical equipment provider’s stock worth $30,623,000 after acquiring an additional 286,011 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Accuray by 31.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,124,803 shares of the medical equipment provider’s stock worth $5,343,000 after acquiring an additional 266,790 shares in the last quarter. 78.86% of the stock is owned by hedge funds and other institutional investors.

Accuray (ARAY) opened at $5.25 on Monday. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44. Accuray has a 52-week low of $3.60 and a 52-week high of $6.00.

ILLEGAL ACTIVITY WARNING: “Analysts Expect Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $91.29 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/04/analysts-expect-accuray-incorporated-aray-will-announce-quarterly-sales-of-91-29-million.html.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Get a free copy of the Zacks research report on Accuray (ARAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.